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Psoriatic arthritis

Original article
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Abstract

Objectives To determine the proportion of patients with
psoriatic arthritis in the Adalimumab Effectiveness in
Psoriatic Arthritis trial achieving minimal disease activity
(MDA) and its individual components at 1 or more visits
over 144 weeks, identify baseline predictors of MDA
achievement, and evaluate the association of MDA status
with independent quality of life (QoL)-related patientreported outcomes (PROs).
►► Prepublication history and
Methods Univariate and multivariate analyses were used
additional material are available.
to identify the baseline characteristics that predicted
To view these files please visit
the journal online (http://dx.doi. achievement of MDA at individual time points (weeks 12
through 144) or sustained MDA (achievement of MDA at 2
org/10.1136/rmdopen-2016-
consecutive time points 12 weeks apart). The association
000415).
of independent QoL-related PROs with MDA achievement
was evaluated at weeks 24 and 144.
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Results In univariate analyses, higher baseline patient
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assessment of pain, tender joint count (TJC), enthesitis and
Health Assessment Questionnaire-Disability Index (HAQ-DI)
score were significantly associated with lower likelihood
of achieving MDA at later time points. Multivariate
analyses confirmed higher baseline HAQ-DI as a significant
predictor for failure to achieve MDA at later time points.
Achievement of sustained MDA was associated with lower
baseline TJC and HAQ-DI score. Achievement of different
MDA components appeared to be treatment dependent.
MDA achievers had significantly better QoL-related PROs
and greater improvements in PROs from baseline to week
24 compared with non-achievers.
Conclusions Higher HAQ-DI score was the most
consistent baseline factor that decreased the likelihood
of achieving MDA and sustained MDA at later time points.
Achieving MDA was associated with better independent
QoL-related PROs.
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Introduction
Psoriatic arthritis (PsA) is a chronic systemic
inflammatory disease that affects the
synovium, tendons, entheses and bone, and
is associated with varied tissue pathology.1 2
PsA is thus characterised clinically by arthritis,
enthesitis and dactylitis in addition to skin
and nail psoriasis.3 4 Approximately 30% of

Key messages
What is already known about this subject?
►► There is limited understanding of patient and disease

characteristics that predict long-term minimal
disease activity (MDA) achievement and potential
benefits associated with achievement of MDA.

What does this study add?
►► The present study provides further insights into the

achievement, prediction and benefits of MDA status
in patients treated with adalimumab.
►► It further confirms higher baseline Health
Assessment Questionnaire-Disability Index as a
significant negative predictor for MDA achievement.
►► MDA achievement was associated with significantly
better quality of life-related patient-reported
outcomes (PROs) and greater improvements in PROs
from baseline.

How might this impact on clinical practice?
►► Our data provide further support for MDA as a

valid treatment target in psoriatic arthritis, since its
achievement is associated with meaningful benefits
in PROs other than those included in the MDA
calculation.

patients with psoriasis develop PsA.2 Joint
damage and functional impairment may
result from uncontrolled disease.1 The European League Against Rheumatism, Group
for Research and Assessment of Psoriasis
and Psoriatic Arthritis, and a PsA treat-totarget task force recommend remission or
low/minimal disease activity (MDA) as treatment targets for patients with PsA.5–7 The
criteria for MDA in PsA were developed8
and validated as a clinically meaningful and
comprehensive treatment target for PsA,9 10
which encompasses skin, joints and entheses.
MDA corresponds to a state of low disease
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activity or remission in PsA,9 11 and patients who achieve
MDA have less radiographic progression and functional
impairment than patients who fail to reach this target.10 12
In the Adalimumab Effectiveness in Psoriatic Arthritis
(ADEPT13) trial, a significantly higher number of patients
treated with adalimumab achieved MDA compared
with those treated with placebo at week 24 (39% vs 7%,
respectively).14 However, the attainment of individual
MDA components in MDA achievers has not been extensively evaluated.15 Identification of MDA components
that are difficult to achieve may ascertain clinical or
pathological factors that merit future attention in disease
management strategies. Additionally, there is limited
understanding of patient and disease characteristics that
predict MDA achievement over longer term and of other
potential benefits associated with achievement of MDA.16
The aim of the present analysis was to determine which
baseline clinical and/or patient demographic characteristics predict the achievement of MDA over 144 weeks in
patients with PsA included in the ADEPT trial and to evaluate the achievement of individual MDA components,
as well as the association of MDA status with independent quality of life (QoL)-related patient-reported
outcomes (PROs) (not included in MDA criteria).
Methods
Patients and study
The methods and primary results of the phase 3, doubleblind, placebo-controlled ADEPT trial (NCT00646386)
of adalimumab in patients with moderately to severely
active PsA are published.13 Briefly, ADEPT patients
were ≥18 years of age, had active PsA (≥3 tender
and ≥3 swollen joints) and an inadequate response or
intolerance to non-steroidal anti-inflammatory drugs.
Patients were randomised 1:1 to receive adalimumab
40 mg or placebo every other week for 24 weeks, after
which they were eligible to enter an extension study in
which they received open-label adalimumab for up to 144
weeks. The present analysis included a subset of ADEPT
patients randomised to adalimumab (n=66) and placebo
(n=69) who had active skin disease at baseline (body
surface area ≥3%) and in whom MDA could be calculated (at least 5/7 MDA components available).
Minimal disease activity
MDA was defined as achieving ≥5 of the following
seven criteria8: tender joint count of 78 joints (TJC) ≤1;
swollen joint count of 76 joints (SJC) ≤1; Psoriasis Area
and Severity Index (PASI) ≤1; patient assessment of
pain (patient pain) ≤15 on a 0–100 mm visual analogue
scale (VAS); Patient Global Assessment of disease activity
(PtGA) ≤20 on a 0–100 mm VAS; Health Assessment Questionnaire-Disability Index (HAQ-DI) ≤0.5; and tender
entheseal points (assessed bilaterally at two sites) ≤1.
Patients who met MDA criteria were termed ‘achievers’
and those who did not were termed ‘non-achievers.’
Sustained MDA was defined as MDA achievement at two
2

consecutive time points 12 weeks apart, except for week
144, where the previous visit was 16 weeks earlier.
Baseline variables tested as predictors of MDA included
age (years), sex, weight (kg), duration of psoriasis or PsA
since diagnosis (years), structural damage measured by
modified total Sharp score, TJC, SJC, PASI (range, 0–72),
C-reactive protein (mg/dL), patient pain, PtGA, HAQ-DI,
enthesitis (absent vs present at two bilateral sites (proximal insertion of Achilles tendon, insertion of plantar
fascia)), Physician Global Assessment of disease activity
(PhGA, 0–100 mm VAS) and Physician Global Assessment of psoriasis (PhGA-P) on a 7-point scale ranging
from severe (very marked plaque elevation, scaling and/
or erythema) to clear (no sign of psoriasis).
Patient-reported outcomes
Health-related QoL was assessed using the Short Form
36 (SF-36) Health Survey questionnaire (total score,
physical component summary score (PCS) and mental
component summary score (MCS)) and Dermatology
Life Quality Index (DLQI). Fatigue was assessed using
the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score.
Statistical analysis
The percentage of patients achieving MDA over time
was assessed using observed data and non-responder
imputation. Baseline characteristics that predicted the
achievement of MDA or sustained MDA at weeks 12,
24, 48, 96 and 144 were identified using univariate and
multivariate analyses. For multivariate analyses, the least
absolute shrinkage and selection operator method was
used to refine baseline variable selection. Penalties were
added to constrain regression coefficients in the presence
of correlated data. The positive predictive value (PPV) or
negative predictive value (NPV) of week 12 MDA status to
determine MDA status at week 24 or 144 was determined
using a two-way contingency table. Analyses of PROs at
week 24 (and for completers at week 144) were based on
observed data, with each analysis conducted on the available data at a particular time point.
Results
Achievement of MDA and sustained MDA through week 144
At the end of the 24-week double-blind period, 36.4%
(24/66) of patients randomised to receive adalimumab
achieved MDA compared with 5.8% (4/69) receiving
placebo while sustained MDA was achieved by 34.8%
(23/66) and 5.8% (4/69) of patients receiving adalimumab and placebo, respectively. At week 24, very
low disease activity, defined as achieving MDA score of
7/7, was attained by 15.4% (10/65) and 0% (0/61) of
patients treated with adalimumab and placebo, respectively. During the open-label period, MDA rate was either
maintained or higher in patients initially randomised to
adalimumab whereas MDA rate was numerically lower
throughout the follow-up in patients switching to openlabel adalimumab after receiving placebo for 24 weeks
Mease PJ, et al. RMD Open 2017;3:e000415. doi:10.1136/rmdopen-2016-000415
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Figure 1 Achievement of MDA over 144 weeks in patients initially receiving adalimumab or placebo during the double-blind
period. Data are presented as observed (solid lines) and using NRI (dashed lines). Patients who escalated to weekly dosing
on or after week 36 were counted as non-responders. Numbers of patients at each study visit are presented below the graph.
ADA, adalimumab; MDA, minimal disease activity; NRI, non-responder imputation; OBS, as observed; PBO, placebo.

(figure 1). Similarly, throughout the open-label period,
the rate of sustained MDA was higher among patients
initially randomised to adalimumab compared with
placebo: week 48, 43.1% (25/58) vs 32.2% (19/59); week
96, 37.9% (22/58) vs 27.1% (16/59); and week 144,
34.5% (20/58) vs 22.0% (13/59). Of the 88 patients who
completed the 144-week open-label period, 15 (17.1%)
achieved MDA at every time point from week 24 through
week 144.
Univariate analysis of factors associated with achievement
of long-term and sustained MDA
In the univariate analysis, higher scores at baseline for
TJC, patient pain and HAQ-DI were significantly associated with lower odds of achieving MDA at every time
point. Higher SJC and higher enthesitis scores or presence of enthesitis at baseline were associated with lower
odds of achieving MDA at most time points (figure 2). At
every time point, lower baseline TJC, SJC and HAQ-DI
scores were associated with higher odds of achieving
sustained MDA (data not shown).
Multivariate analysis of factors associated with
achievement of long-term and sustained MDA
Multivariate analysis confirmed higher baseline HAQ-DI
score as a significant predictor for failure to achieve MDA
at later time points (figure 3). A 1-unit increase in baseline HAQ-DI reduced the odds of achieving MDA at later
time points by 64%–77%. Lower age, TJC and HAQ-DI
at baseline were associated with sustained MDA at week
48, and lower enthesitis at baseline was associated with
sustained MDA at week 144 (online supplementary figure
1).
Mease PJ, et al. RMD Open 2017;3:e000415. doi:10.1136/rmdopen-2016-000415

Prediction of MDA at later time points based on MDA status
at week 12
MDA status at week 12 had a 100% PPV, 95.7% NPV,
100% specificity and 85.2% sensitivity for predicting
MDA status at week 24. MDA status at week 12 had 100%
PPV, 64.7% NPV, 100% specificity and 40.0% sensitivity
for predicting MDA status at week 144. The high NPV
(95.7%) for prediction of week 24 MDA status indicated a good ability of week-12 MDA non-achievement
to predict MDA non-achievement at week 24. However,
the moderate NPV (64.7%) for prediction of week-144
MDA status indicated a poor ability of week-12 MDA
non-achievement to predict MDA non-achievement at
week 144.
Achievement of individual MDA components
The comparison of individual MDA components at baseline between MDA achievers and non-achievers at week
24 is presented in online supplementary table 1. MDA
achievers, especially those receiving placebo, trended
towards lower mean scores for the individual MDA
components at baseline.
At week 24, in adalimumab-treated patients regardless of their MDA status, SJC≤1 (MDA achievers, 58.3%
(14/24); MDA non-achievers, 13.5% (5/37)) and TJC≤1
(MDA achievers, 83.3% (20/24); MDA non-achievers,
10.8% (4/37)) were achieved by the smallest number
of patients; whereas in patients treated with placebo,
PASI was achieved by the lowest number of patients
(MDA achievers, 0% (0/4); MDA non-achievers, 3.6%
(2/55), table 1). Although a high proportion of MDA
achievers and non-achievers satisfied the enthesitis
3
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Figure 2 OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. CRP,
C-reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; MDA, minimal disease activity; mTSS, modified
total Sharp score; PASI, Psoriasis Area and Severity Index; PhGA, Physician Global Assessment of disease activity; PhGA-P,
Physician Global Assessment of psoriasis; Ps, psoriasis; PsA, psoriatic arthritis; PtGA, Patient Global Assessment of disease
activity; SJC, swollen joint count of 76 joints; TJC, tender joint count of 78 joints. *Statistically significant predictor of MDA.

criterion throughout the study, fewer than half of the
patients (adalimumab, 41.7% (25/60); placebo, 39.0%
(23/59)) had baseline entheseal involvement in ≥1 of
the two enthesial sites assessed. The differences between
the rates of achieving individual MDA components
were less pronounced during the open-label period
(online supplementary file 3). At week 144, in patients
initially treated with placebo, patient pain ≤15 and TJC≤1
were the two MDA components that were consistently met
by the lowest number of patients and could therefore be

considered the limiting components for achieving MDA
after delayed adalimumab introduction (online supplementary file 3).
To evaluate the contribution of each individual MDA
component to MDA achievement at the group level, individual MDA components were omitted separately from
the MDA calculation (MDA 5/6, defined as achievement
of ≥5 of 6 criteria). Exclusion of SJC did not impact the
MDA 5/6 rate at week 24 in patients treated with adalimumab, whereas exclusion of TJC or PASI decreased MDA

4
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Figure 3 OR for selected baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by multivariate analysis of observed
data. Statistically significant variables in the univariate analysis were further selected with LASSO to adjust for confounding
factors and collinearity. HAQ-DI, Health Assessment Questionnaire-Disability Index; LASSO, least absolute shrinkage and
selection operator method; MDA, minimal disease activity; PASI, Psoriasis Area and Severity Index; Ps, psoriasis; SJC, swollen
joint count of 76 joints; TJC, tender joint count of 78 joints. *Statistically significant predictor of MDA.

achievement by 3.2%; exclusion of patient pain, PtGA,
HAQ-DI or enthesitis decreased MDA achievement by
6.5%. This suggested a relatively equal contribution of
individual MDA components to achieving MDA at the
population level.
Relationship between disease duration and HAQ-DI
We next explored the relationship between HAQ-DI,
a negative predictor of MDA achievement, and disease
duration. Generally, HAQ-DI increased with longer PsA
duration both at baseline as well as at various study time
points (figure 4), but the correlation between PsA duration and HAQ-DI was weak (correlation coefficient <0.3).
The mean HAQ-DI score exceeded 0.5 at weeks 96 and
144 in patients with PsA duration of >8 years (figure 4),
suggesting that in a substantial proportion of patients
with long-standing PsA, the impairment in physical
function related to irreversible damage could prevent
Mease PJ, et al. RMD Open 2017;3:e000415. doi:10.1136/rmdopen-2016-000415

achievement of this MDA criterion even with effective
control of inflammation.
QoL-related PROs associated with MDA achievement
At week 24, independent QoL-related PROs (those not
included in the MDA criteria) were significantly better in
MDA achievers than MDA non-achievers (figure 5A,B),
including higher mean SF-36 total (p<0.001), PCS
(p<0.001) and MCS (p<0.01) scores, higher FACIT-F
score (p<0.001) and lower DLQI score (p<0.001). MDA
achievers at week 24 had favourable mean (±SD) PRO
scores at baseline compared with MDA non-achievers
for SF-36 total (58.0±19.0 vs 46.5±19.7; p<0.01) and
PCS (37.7±12.0 vs 31.6±9.1; p<0.01) scores, as well as
FACIT-F (34.9±10.9 vs 29.2±12.2; p<0.05) scores, but
not SF-36 MCS (48.2±11.0 vs 45.6±12.1; p=0.314) and
DLQI (7.9±5.6 vs 9.7±7.4; p=0.243) scores. Age, sex,
PsA duration and methotrexate use did not influence
5
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Table 1 Attainment of individual MDA components in MDA achievers and non-achievers at week 24 by randomised
treatment
MDA achievers

MDA non-achievers

Patients meeting
criterion, n (%)

Patients meeting
criterion, n (%)

MDA component

Adalimumab Placebo
(n=24)
(n=4)

Response difference Adalimumab
(95% CI)
(n=37)

Placebo
(n=55)

Response difference
(95% CI)

TJC≤1

20 (83.3)

3 (75.0)

8.3 (–36.6 to 53.3)

4 (10.8)

3 (5.5)

5.4 (–6.3 to 17.0)

SJC≤1

14 (58.3)

2 (50.0)

8.3 (–44.9 to 61.2)

5 (13.5)

6 (10.9)

2.6 (–11.2 to 16.4)

PASI≤1

21 (87.5)

0

87.5 (74.3 to 100)*

15 (40.5)

2 (3.6)

36.9 (20.3 to 53.5)**

Patient pain ≤15

24 (100)

4 (100)

0

6 (16.2)

3 (5.5)

10.8 (–2.6 to 24.1)

PtGA≤20

24 (100)

4 (100)

0

6 (16.2)

7 (12.7)

3.5 (–11.3 to 18.3)

HAQ-DI≤0.5

23 (95.8)

4 (100)

–4.2 (–12.2 to 3.8)

8 (21.6)

17 (30.9)

–9.3 (–27.3 to 8.7)

Tender entheseal
points ≤1

24 (100)

4 (100)

0

26 (70.3)

35 (63.6)

6.6 (–12.8 to 26.1)

**p<0.001; *p<0.01.
HAQ-DI, Health Assessment Questionnaire-Disability Index; MDA, minimal disease activity; PASI, Psoriasis Area and Severity Index; PtGA,
Patient Global Assessment of disease activity; SJC, swollen joint count of 76 joints; TJC, tender joint count of 78 joints.

results for SF-36, FACIT-F or DLQI in MDA achievers
versus MDA non-achievers (data not shown).
Furthermore, MDA achievers experienced larger mean
changes from baseline for the evaluated PROs than MDA
non-achievers (figure 5C,D); these changes reached
the established minimal clinically important difference
(MCID) for all the evaluated PROs.17 Although the mean
change from baseline in SF-36 total and PCS scores for
MDA non-achievers reached the MCID, these changes
were of a lower magnitude compared with MDA achievers.
For patients who completed 144 weeks, no significant
differences in PRO scores were observed between MDA
achievers and non-achievers at the end of follow-up (data
not shown).
Discussion
MDA has been established as a validated composite
outcome measure in PsA that is discriminative and has
prognostic value in terms of structural damage. Further,

its use as a treatment target in the first treat-to-target trial
in PsA (TIght COntrol of Psoriatic Arthritis; TICOPA)
resulted in improved joint, skin and PROs compared
with standard care following no treatment target.18 19
With the trend for increased use of MDA as a clinical trial
endpoint, as well as its adoption into clinical practice,5 6 it
is important to fully understand predictors of MDA and
the contribution of individual MDA components to the
overall MDA achievement, as well as potential associations of MDA status with other outcomes. The current
analysis provided insights into the achievement, prediction and benefits of MDA that were obtained within the
randomised, placebo-controlled ADEPT trial of adalimumab, including its open-label extension through week
144.
Nearly 40% of patients treated with adalimumab were
previously reported to have achieved MDA by the end
of the 24-week, double-blind period of ADEPT.14 The
present analysis showed that the proportion of patients

Figure 4 Box plot of HAQ-DI scores at baseline, week 96 and week 144 categorised by baseline PsA duration. The horizontal
lines indicate the median, boxes mark the interval between the 25th and 75th percentiles, vertical lines indicate the maximum
and minimum values, and + represents the mean. The dashed line represents HAQ-DI=0.5, which is the cut-off point for the
MDA component. HAQ-DI, Health Assessment Questionnaire-Disability Index; MDA, minimal disease activity; PsA, psoriatic
arthritis.

6
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Figure 5 Mean of SF-36 and FACIT-F (A) and DLQI (B) scores at week 24 and mean change from baseline to week 24 in SF36 and FACIT-F (C) and DLQI (D) scores in MDA achievers and MDA non-achievers. Data are presented as observed. Dashed
lines represent MCID. *p<0.01; **p<0.01; ***p<0.001. DLQI, Dermatology Life Quality Index; FACIT-F, Functional Assessment of
Chronic Illness Therapy-Fatigue; MCID, minimal clinically important difference; MCS, mental component score; MDA, minimal
disease activity; PCS, physical component score; SF-36, Short Form 36 Health Survey.

with MDA was maintained or increased through the end
of the 144-week open-label extension period, reaching
up to 50% in patients initially treated with adalimumab.
This observed MDA rate is consistent with findings in
the open-label extension of a randomised controlled
trial with golimumab12 and observational studies with
antitumour necrosis factors (TNFs) in clinical practice
settings.9 16 20 21 A fairly consistent proportion of patients
(37%–40%) had sustained MDA, which was also in
accordance with previous data.9 12 This adds to the body
of evidence that long-term sustained MDA is achievable with anti-TNF therapy in up to 50% of patients
with established PsA.9 12 16 20 In a recent study, <20%
of patients treated with methotrexate achieved MDA
Mease PJ, et al. RMD Open 2017;3:e000415. doi:10.1136/rmdopen-2016-000415

at 6 months, providing further evidence in support of
early introduction of anti-TNF therapy.22 At week 24,
15.4% of patients treated with adalimumab achieved an
MDA score of 7/7, which was recently proposed as very
low disease activity.23 This MDA 7/7 rate is consistent
with the rates reported in patients receiving anti-TNF
therapy.24
Patients initially randomised to placebo arm were slow
to attain MDA following treatment with open-label adalimumab. Interestingly, the MDA rate among patients
initially treated with placebo remained consistently lower
compared with patients who initially received adalimumab through 144 weeks. Although the differences
did not reach statistical significance at any time point,
7
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this may indicate that delay in introduction of effective
therapy could negatively impact MDA achievement, even
in patients with long-standing PsA.
Higher scores at baseline for TJC, SJC, patient pain,
enthesitis and HAQ-DI were significantly associated
with lower odds of achieving MDA at most time points,
including sustained MDA, by univariate analysis. Multivariate analysis confirmed high baseline HAQ-DI score as
the most consistent predictor for failure to achieve MDA.
A 1-unit increase in baseline HAQ-DI reduced the odds of
achieving MDA at later time points by 64%–77%. Consistent with our results, worse physical function (measured
by HAQ-DI) was most commonly identified as a negative
predictor of MDA in prior studies,9 12 16 21 25 whereas other
predictive factors varied across studies.9 12 16 20 21 25 26 In
patients with longer disease duration, the mean HAQ-DI
scores remained high even after long-term adalimumab
treatment. This suggests that in patients with effective
control of inflammation, higher HAQ-DI was most likely
due to irreversible structural damage. Previous studies
have shown that the onset of disease symptoms of less
than 6 or 12 months prior to starting treatment is associated with better long-term function outcomes.27 28 This
analysis, where higher baseline HAQ-DI scores were
observed in established disease and associated with lower
MDA achievement, further supports the need for early
and effective treatment in PsA.
In patients who achieved MDA at week 24, the baseline scores for individual MDA components were lower,
suggesting that patients with milder disease achieve MDA
more easily. Achieving MDA early (at week 12) was a
strong predictor of MDA response at weeks 24 and 144.
Although not achieving MDA early remained a good
predictor of non-MDA status at week 24, the ability of
week-12 MDA non-response to predict non-response at
week 144 was relatively poor. Therefore, not achieving
MDA at week 12 should not result in an immediate
change to another therapy.
The joint responses (TJC and SJC criteria) appeared
to limit MDA achievement in patients treated with adalimumab at the end of the double-blind period, whereas
fewer differences in the attainment of individual MDA
components were observed during prolonged adalimumab therapy. This could indicate more equivalent
long-term adalimumab effectiveness across different
MDA components, but could also be biased by the
observed analysis in the open-label period. By contrast,
patients treated with placebo had difficulty meeting the
PASI criterion, which was not fulfilled by any of the MDA
achievers and also not met by the highest percentage of
MDA non-achievers at week 24. These findings suggest
that fulfilment of individual MDA components may be
treatment dependent. A previous study reported a highly
active skin component still present in patients otherwise
meeting MDA criteria; however, details of PsA therapy
were not presented.15
Patients who achieved MDA at week 24 had significantly better PROs reflecting improved QoL and fatigue.

Furthermore, the MDA achievers experienced larger
improvements from baseline than non-achievers in
all PROs measured. The mean change from baseline
reached MCID for all PROs in MDA achievers but not
MDA non-achievers. Previous studies demonstrated
lower radiographic progression and improvements in
PROs which were included in the MDA criteria in MDA
achievers compared with non-achievers.6 8 Our data
provide further support for MDA as a valid treatment
target in PsA that is associated with meaningful benefits
as measured by PROs beyond those included in the MDA
calculation.
The limitations of our analyses include the low patient
numbers and the fact that ADEPT was not specifically designed to assess MDA achievement a priori.
However, these limitations exist for most other studies of
MDA9 12 16 20 21 25 26 and, along with different patient populations and treatments, may explain inconsistent findings
on MDA predictors other than HAQ-DI. A recent study
reported that patients with PsA and with fibromyalgia had lower likelihood of achieving MDA.29 Given
that fibromyalgia was not an exclusion criterion in the
ADEPT study and systematic assessment for fibromyalgia
was not performed, the impact of comorbid fibromyalgia
cannot be assessed. Strengths of our post hoc analyses
include a 24-week placebo-controlled period, enabling a
comparison that is lacking in observational studies, and
the relatively long open-label extension period with adalimumab treatment.
In summary, the present study provides further insights
into the long-term achievement of MDA in patients
treated with adalimumab and confirms higher baseline
HAQ-DI as a negative predictor for the achievement
of MDA, supporting the necessity for early and effective treatment in PsA before irreversible functional
impairment occurs. Finally, it demonstrates that improvements in QoL-related PROs are associated with MDA
achievement, which lends further support to MDA as a
meaningful treatment target in PsA.

8
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